Strand Life Sciences, Orlando, Fla, has released the latest version of its bioinformatics flagship product, Strand NGS to address recent challenges in next-generation sequencing (NGS).
Current cross-cohort RNA- and small-RNA-Seq studies span tens of replicates and batches across hundreds of samples, sometimes conducted across several different institutions. For such studies, Strand NGS v3.1 includes confounding variable analysis to eliminate technical effects, including batch effects; the t-SNE plot; profile and heat-map plots of gene-body coverage; and several other visual enhancements.
The second new feature is support for unique molecular identifiers (UMIs) for DNA-, RNA-, and small-RNA-Seq. UMI support in Strand NGS is end to end, spanning alignment to variant calling in DNA-Seq, and alignment to quantification in RNA- and small-RNA-Seq. The Bioo Scientific, Qiagen, and Rubicon UMI protocols are natively supported, and an intuitive interface allows the specification of custom UMI protocols.
Vamsi Veeramachaneni, Strand Life Sciences.
“For liquid biopsies and low-grade formalin-fixed paraffin-embedded samples, UMI support in DNA-Seq enables the detection of somatic variants at low concentrations,” says Vamsi Veeramachaneni, PhD, chief scientific officer at Strand Life Sciences. “In RNA-Seq, large-scale and UMI support can be used in single-cell-based studies that reveal tumor-cell heterogeneity, even at low concentrations.”
Ramesh Hariharan, PhD, Strand Life Sciences.
“At Strand, we are continuously working toward improving the accuracy and efficiency of NGS data analysis,” says Ramesh Hariharan, PhD, chief executive at Strand Life Sciences. “Customers can look forward to Strand NGS becoming available on the Cloud in the near future.”
For more information, visit Strand Life Sciences.
